IDEXX Laboratories Aktie
| 416,33USD | -3,70USD | -0,88% |
WKN: 888210 / ISIN: US45168D1046
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 99,01 |
| The Vanguard Group, Inc. | 11,79 |
| Vanguard Group, Inc. (Subfiler) | 11,33 |
| State Street Corp. | 4,39 |
| BlackRock Fund Advisors | 4,36 |
| AllianceBernstein LP | 3,42 |
| Fundsmith LLP | 3,24 |
| Vanguard Total Stock Market ETF | 3,17 |
| Fundsmith Equity Fund | 3,06 |
| Geode Capital Management LLC | 2,75 |
| Vanguard 500 Index Fund | 2,62 |
| BlackRock Institutional Trust Co. NA | 2,40 |
| BAMCO, Inc. | 2,34 |
| Vanguard Mid Cap Index Fund | 2,12 |
| Invesco QQQ Trust | 1,94 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 9 200 | 9 300 | 10 350 | 10 780 | 11 000 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,26 | 0,29 | 0,31 | 0,31 | 0,33 |
Bilanz (in Mio. USD) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 635 | 1 013 | 900 | 1 044 | 1 441 |
| Summe Anlagevermögen | 1 197 | 1 281 | 1 537 | 1 703 | 1 819 |
| Summe Aktiva | 1 832 | 2 295 | 2 437 | 2 747 | 3 260 |
Bilanz (in Mio. USD) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 1 070 | 1 003 | 1 031 | 1 470 | 1 067 |
| Summe Fremdkapital | 1 655 | 1 662 | 1 747 | 2 138 | 1 775 |
| Summe Eigenkapital | 178 | 633 | 690 | 609 | 1 485 |
| Summe Passiva | 1 832 | 2 295 | 2 437 | 2 747 | 3 260 |
Adresse
| One IDEXX Drive, 04092-2040 Westbrook | |
| Telefon | +1 (207) 556-0300 |
| Fax | +1 (207) 556-4346 |
| Internet | http://www.idexx.com |
Management
|
Asha S. Collins
Independent Director |
|
Brian Patrick McKeon
Chief Financial Officer, Treasurer & Executive VP |
|
Bruce L. Claflin
Independent Director |
|
Daniel M. Junius
Independent Director |
|
George J. Fennell
Chief Revenue Officer & Senior Vice President |
|
Irene Chang Britt
Independent Director |
|
Jeffery Donn Chadbourne
SVP-Commercial Finance & Sales Operations |
|
John Hart
Senior Vice President-Global Operations |
|
John Ravis
Investor Relations Contact |
|
Jonathan J. Mazelsky
President, Chief Executive Officer & Director |
|
Ken Grady
Chief Information Officer & Senior VP |
|
Kerry Bennett
SVP, GM-Product, Strategy & Global Reference Labs |
|
Lawrence D. Kingsley
Non-Executive Chairman |
|
M. Anne Szostak
Independent Director |
|
Martin Alexander Smith
Chief Technology Officer & Executive VP |
|
Michael Erickson
EVP & GM-Point of Care Diagnostics & Telemedicine |
|
Michael J. Lane
Executive VP, GM-Reference Laboratories & IT |
|
Michael P. Johnson
Chief Human Resources Officer & Executive VP |
|
Michael Schreck
EVP, GM-Corporate Accounts & Customer Experience |
|
Murthy Yerramilli
Senior Vice President-Research & Development |
|
Sam A. Samad
Independent Director |
|
Sharon E. Underberg
Secretary, Executive VP & General Counsel |
|
Sophie V. Vandebroek
Independent Non-Executive Director |
|
Stuart M. Essig
Independent Director |
|
Tina Hunt
Executive Vice President-Strategy |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
